Tag
Butyrylcholinesterase (BuChE) modulates hepatic stellate cell activation by degrading acetylcholine, mitigating fibrogenesis via muscarinic receptor signaling and offering a new therapeutic target for liver fibrosis.
Subclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction and
This article reviews evidence linking cardiovascular-kidney-metabolic syndrome stages to liver fibrosis severity, progression, and liver-related events in metabolic dysfunction-associated steatotic liver disease (MASLD). Higher CKM stages i
This mediation analysis of a phase 2 MASH trial reveals that survodutide improves liver inflammation and fibrosis predominantly through weight-independent mechanisms, highlighting a potential direct hepatic effect beyond weight reduction.
A liver fibrosis risk score (pFIB-6) identifies children with obesity at markedly increased short-term risk of type 2 diabetes, offering a potential tool for early risk stratification.
The G-MASLD study evaluated the diagnostic accuracy of non-invasive fibrosis tests across 41 countries, revealing regional variability and identifying Agile-3+ and Agile-4 as the most accurate for advanced fibrosis and cirrhosis in MASLD pa
This article explores the mechanism by which HBV induces liver fibrosis through pyruvate-dependent ROS production and PPARα inhibition, highlighting novel therapeutic targets for chronic hepatitis B management.
This article explores a novel AI framework that identifies distinct collagen deposition patterns in MASLD, offering improved molecular specificity and prognostic value beyond traditional fibrosis assessments.
A validation study suggests current liver fibrosis screening criteria are too broad. A refined risk-based approach reduced eligibility from 60–76% to 10–22% of adults while improving the yield of elevated liver stiffness and predicting futu
This review synthesizes the evolving landscape of noninvasive tests (NITs) in MASH, detailing their role as surrogate endpoints for adverse outcomes and therapeutic response based on recent clinical trials and meta-analyses.
This study identifies the integrin αV-YAP-CTGF axis in liver sinusoidal endothelial cells as a primary driver of fibrosis and carcinogenesis in congestive hepatopathy. By targeting this mechanosensitive pathway, researchers demonstrated a s
Researchers have identified a mechanosensitive signaling pathway in liver sinusoidal endothelial cells that drives fibrosis and cancer in response to chronic congestion, offering a new therapeutic target for heart-failure-related liver dise
Researchers have identified a novel signaling pathway in liver sinusoidal endothelial cells (LSECs) that drives fibrosis and liver cancer in congestive hepatopathy. The study highlights the Integrin αV-YAP-CTGF axis as a critical mechanism
This review synthesizes recent findings on how mechanical stress in congestive hepatopathy activates the Integrin αV-YAP-CTGF pathway in liver sinusoidal endothelial cells, leading to fibrosis and liver cancer.
A large-scale longitudinal study reveals that obesity and diabetes synergistically amplify the risk of advanced liver disease in individuals with Alpha-1 Antitrypsin Deficiency (AATD), while also identifying a complex relationship between b
The Phenome India study identifies a 38.9% age-adjusted prevalence **Constructing the JSON Object** Now, I’m carefully constructing the JSON object, which needs to be a valid, parseable string. I’m focusing on incorporating the
The Phase 2 trial of efimosfermin alfa (BOS-580) shows that once-monthly dosing is safe and well-tolerated in patients with MASH and F2/F3 fibrosis, supporting its continued clinical development as a potential liver-targeted therapy.
The SYNERGY-NASH trial demonstrates that Tirzepatide significantly improves MASH resolution and liver fibrosis. This effect is driven by substantial weight loss, improved glycemic control, and liver fat normalization, highlighting a transfo
A target-trial emulation of 4,476 matched T2DM patients with early MASLD found GLP-1RA use was associated with a 25% lower hazard of progression to high-risk FIB‑4 versus DPP‑4i (HR 0.75); no difference was seen for hard liver outcomes.
A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑inter
